The BioCarta RAS signature, the HRAS signature, and the KRAS signature were tested for their diagnostic capabilities in human lung cancer using a gene expression dataset with 45 adenocarcinoma lung cancer samples and 48 squamous lung cancer samples [25]. The gene discussed is KRAS; the disease is lung carcinoma.